Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.68 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.61 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.61 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.61 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.59 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | LTA4H | P09960 | 2/20 | 0.57 |
| ▸ | KDR | P35968 | 2/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13883476 | 0.86 | HRH3 (0.61) | HRH3PSMB1PSMB5PSMB2KDM4E | |
| SCHEMBL3611053 | 0.86 | HRH3 (0.61) | HRH3PSMB1PSMB5PSMB2KDM4E | |
| SCHEMBL3026592 | 0.81 | PSMB1 (0.75) | HRH3PSMB1PSMB5PSMB2KDM4E | |
| SCHEMBL30969263 | 0.79 | PSMB1 (0.78) | HRH3PSMB1PSMB5PSMB2KDM4E | |
| SCHEMBL5176439 | 0.79 | KDR (0.65) | HRH3PSMB1PSMB5LTA4HKDR | |
| SCHEMBL5565308 | 0.78 | LTA4H (0.74) | HRH3LTA4HKCNH2 | |
| Hydrochloric Acid SCHEMBL5176435 | 0.78 | KDR (0.64) | HRH3LTA4HKDRKCNH2EPHX2 | |
| SCHEMBL4167205 | 0.78 | PSMB1 (0.60) | HRH3PSMB1PSMB5PSMB2KDM4E | |
| SCHEMBL19145673 | 0.78 | LTA4H (0.59) | HRH3PSMB1PSMB5PSMB2KDM4E | |
| SCHEMBL5174922 | 0.78 | HRH3 (0.65) | HRH3PSMB1PSMB5PSMB2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1687285-B1 | THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-03-05 | — | — | EP | disclosed |
| US-7795288-B2 | Thiazole and pyrazole derivatives as Flt-3 kinase inhibitors | NOVARTIS AG (CH) | 2010-09-14 | — | — | US | disclosed |
| US-20070167449-A1 | Thiazole and pyrazole derivatives as flt-3 kinase inhibitors | NOVARTIS PHARMA AG (CH) | 2007-07-19 | — | — | US | disclosed |
| EP-1687285-A1 | THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS | Novartis AG (CH) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005047273-A1 | THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167449-A1 | Thiazole and pyrazole derivatives as flt-3 kinase inhibitors | FLT3, FLT1, FLT4 | HRH3 1666/4885PSMB1 4743/4885PSMB5 4563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.